sc10914
Small moleculeexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2016 (NCT02940132)
Timeline
Indications
Mechanism of action
- Poly [ADP-ribose] polymerase 10INHIBITOR
PARP10 inhibitor
- Poly [ADP-ribose] polymerase 2INHIBITOR
PARP2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- sc10914
- sc10914
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04556539 | Phase 2 | Sep 30, 2020 | Qingfeng Pharmaceutical Group |
| NCT04556292 | Phase 2 | Aug 12, 2020 | Fudan University, Qingfeng Pharmaceutical Group |
| NCT02940132 | Phase 1 | Oct 1, 2016 | Peking University, Qingfeng Pharmaceutical Group |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Qingfeng Pharmaceutical Group | For profit | 3 | 3 | 2 | 2016 |
| Fudan University | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Peking University | Academic/Hospital | 1 | 0 | 1 | 2016 |
3 organizations
Page 1 / 1